These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 1780767

  • 1. Thrombogenicity associated with factor IX complex concentrates.
    Lusher JM.
    Semin Hematol; 1991 Jul; 28(3 Suppl 6):3-5. PubMed ID: 1780767
    [No Abstract] [Full Text] [Related]

  • 2. [Clinical use of factor IX concentrates].
    Nyman D.
    Schweiz Med Wochenschr; 1975 Sep 13; 105(37):1188-90. PubMed ID: 1215901
    [Abstract] [Full Text] [Related]

  • 3. Factor IX thrombogenicity: in vivo effects on coagulation activation and a case report of disseminated intravascular coagulation.
    Small M, Lowe GD, Douglas JT, Forbes CD, Prentice CR.
    Thromb Haemost; 1982 Aug 24; 48(1):76-7. PubMed ID: 7135346
    [Abstract] [Full Text] [Related]

  • 4. Monoclonal antibody-purified factor IX--comparative thrombogenicity to prothrombin complex concentrate.
    Kim HC, Matts L, Eisele J, Czachur M, Saidi P.
    Semin Hematol; 1991 Jul 24; 28(3 Suppl 6):15-9. PubMed ID: 1780766
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Recombinant factor IX for the treatment of hemophilia B. Introduction.
    Thompson A.
    Semin Hematol; 1998 Apr 24; 35(2 Suppl 2):1-3. PubMed ID: 9565159
    [No Abstract] [Full Text] [Related]

  • 14. Preclinical studies of recombinant factor IX.
    Schaub R, Garzone P, Bouchard P, Rup B, Keith J, Brinkhous K, Larsen G.
    Semin Hematol; 1998 Apr 24; 35(2 Suppl 2):28-32. PubMed ID: 9565164
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Properties of commercial factor IX concentrates.
    Coan MH, Fournel MA, Mozen MM.
    Ann N Y Acad Sci; 1981 Apr 24; 370():731-46. PubMed ID: 6168231
    [No Abstract] [Full Text] [Related]

  • 17. A safe approach to treatment of factor IX-deficient patients. Introduction and overview of treatment.
    Aledort LM.
    Semin Hematol; 1991 Jul 24; 28(3 Suppl 6):1-2. PubMed ID: 1780765
    [No Abstract] [Full Text] [Related]

  • 18. Combined factor IX and protein C deficiency in a child: thrombogenic effects of two factor IX concentrates.
    Negrier C, Vial J, Vinciguerra C, Berruyer M, Dechavanne M.
    Am J Hematol; 1995 Feb 24; 48(2):120-4. PubMed ID: 7847325
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.